Abstract
Introduction: Psoriasis (PsO) is currently regarded as a systemic inflammatory disease with a growing burden of post-diagnosis associated comorbidities. To determine the initial burden of comorbiditis we evaluated the comorbidome at PsO onset. Methods: In a matched case–control study, we extracted data on 57,228 patients and 125 morbidities from the Clalit Health Services Israeli insurance database. PsO cases were matched with control individuals by sex and age at enrolment. As pre-existing comorbidities, we considered all conditions already present in controls at the same age as the matched PsO case at the time of their diagnosis. To test for differences in the odds of comorbidities between the case and control groups, logistic regression analyses were run to calculate the odds ratio (OR) for each comorbidity, after which the comorbidome was graphically represented. Results: In this study we enrolled 28,614 PsO patients and 28,614 controls with an average age of 45.3 ± 19.6 years. At the time of diagnosis, PsO patients were more likely to be diagnosed with 2–4 comorbidities (28.8% vs 23.8%) and > 5 (19.6% vs 12.9%,). PsO patients’ specific comorbidomes evidenced several pathological cores: autoimmune and inflammatory systemic diseases [i.e., hidradenitis suppurativa (OR 3.55, 95% CI 1.88–7.28) or polymyalgia rheumatica (OR 3.01 95% CI 1.96–4.77)], inflammatory bowel diseases [i.e., Crohn’s disease (OR 2.99 95% CI 2.20–4.13)], pulmonary inflammatory diseases [i.e., chronic obstructive pulmonary disease (OR 1.81 95% CI 1.61–2.04)], hepatological diseases [i.e., cirrhosis (OR 2.00 95% CI 1.36–3.00)], endocrine diseases [dysthyroidisms (OR 1.82 95% CI 1.30–2.59)], mental disorders [i.e., depression (OR 1.72 95% CI 1.57–1.87)], and cardiovascular diseases (i.e., hypertension (OR 1.47 95% CI 1.41–1.53)]. Conclusion: The PsO-onset comorbidome may help health professionals plan more comprehensive patient management. By screening for these common PsO-linked conditions, early diagnosis and treatment may become more frequent, thus greatly benefiting patients on their medical journey.
| Original language | English |
|---|---|
| Pages (from-to) | 2093-2105 |
| Number of pages | 13 |
| Journal | Dermatology and Therapy |
| Volume | 13 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2023 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2023, The Author(s).
Funding
AB: conceptualization and design of the study, interpretation of results, critical revision of the article content. AM: writing and editing the manuscript. CC: preparation of figures and tables for publication, statistical analysis and modelling, data curation and management. ARB: data analysis. RLB: writing and editing the manuscript. SRM: literature review and background research. FNP: literature review and background research. KK: data collection, supervision. AC: data collection, supervision. GD: literature review and background research, critical revision of the article content. The authors have no conflicts of interest to declare. The Human Investigation Committee of Ben-Gurion University of the Negev, Beersheba, Israel, approved this study and granted an exemption from informed consent. No funding or sponsorship was received for this study or publication of this article. The authors declare that the data from their research is available upon reasonable request from the corresponding author.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Comorbidome
- Precision medicine
- Psoriasis
- Systemic inflammation
- Treatment
Fingerprint
Dive into the research topics of 'The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver